15 March 2024 in PLOS Pathogens
LAL'Emir Wassim El Ayoubi
Ebola disease (EBOD) remains a significant and ongoing threat to African countries, characterized by a mortality rate of 25% to 90% in patients with high viral load and significant transmissibility. The most recent outbreak, reported in Uganda in September 2022, was declared officially over in January 2023. However, it was caused by the Sudan Ebola virus (SUDV), a culprit species not previously reported for a decade. Since its discovery in 1976, the management of EBOD has primarily relied on supportive care. Following the devastating outbreak in West Africa from 2014 to 2016 secondary to the Zaire Ebola virus (EBOV), where over 28,000 lives were lost, dedicated efforts to find effective therapeutic agents have resulted in considerable progress in treating and preventing disease secondary to EBOV. Notably, 2 monoclonal antibodies—Ebanga and a cocktail of monoclonal antibodies, called Inmazeb—received Food and Drug Administration (FDA) approval in 2020. Additionally, multiple vaccines have been approved for EBOD prevention by various regulatory bodies, with Ervebo, a recombinant vesicular stomatitis virus-vectored vaccine against EBOV being the first vaccine to receive approval by the FDA in 2019. This review covers the key signs and symptoms of EBOD, its modes of transmission, and the principles guiding supportive care. Furthermore, it explores recent advancements in treating and preventing EBOD, highlighting the unique properties of each therapeutic agent and the ongoing progress in discovering new treatments.
29 December 2022 in Clinical Hematology International
With the rising number of patients undergoing hematopoietic stem cell transplantation (HSCT), clinicians are more likely to encounter infectious complications in immunocompromised hosts, particularly cytomegalovirus (CMV) infection. Besides the high mortality of CMV end-organ disease, patients with detectable CMV viremia may have worse outcomes and decreased survival even in the absence of end-organ disease. In view of the implications on morbidity and mortality, clinicians should maintain a high index of suspicion and initiate antiviral drugs promptly when CMV infection is confirmed. High-risk patients should be identified in order to provide optimal management. Additionally, novel antiviral agents with a good safety profile and minor adverse events are now available for prophylaxis in high-risk patients and for treatment of resistant or refractory CMV infection. The following review provides concise, yet comprehensive, guidance on the burden and risk factors of CMV in this population, as well as an update on the latest evidence for the management of CMV infection.
28 October 2023 in Journal of Infection and Public Health
Despite multiple reports of increased incidence of bacterial respiratory tract infections following COVID-19 globally, the microbiology is not yet fully elucidated. In this study, we describe the microbiology of bacterial infections and the prevalence of multidrug resistant organisms (MDROs) in hospitalized COVID-19 patients with community-acquired pneumonia (CAP), and hospital-acquired pneumonia (HAP) which includes both non-ventilated hospital acquired pneumonia (NVHAP) and ventilator-associated pneumonia (VAP). To our knowledge, this is the first study that compares the microbiology of VAP and NVHAP in COVID-19 patients. This is a longitudinal retrospective cohort study conducted at the American University of Beirut Medical Center (AUBMC), a tertiary-care centre in Lebanon. Adult patients with confirmed COVID-19 and concurrent bacterial respiratory infections with an identifiable causative organism who were hospitalized between March 2020 and September 2021 were included. Bacterial isolates identified in hospital-acquired pneumonia (HAP) were divided into 3 groups based on the time of acquisition of pneumonia after admission: hospital day 3-14, 15-28 and 29-42. Out of 1674 patients admitted with COVID-19, 159 (9.5%) developed one or more respiratory infections with an identifiable causative organism. Overall, Gram-negative bacteria were predominant (84%) and Stenotrophomonas maltophilia was the most common pathogen, particularly in HAP. Among 231 obtained isolates, 59 (26%) were MDROs, seen in higher proportion in HAP, especially among patients with prolonged hospital stay (> 4 weeks). Non-fermenter Gram-negative bacilli (NFGNB) (OR = 3.52, p-value<0.001), particularly S. maltophilia (OR = 3.24, p-value = 0.02), were significantly more implicated in VAP compared to NVHAP. NFGNB particularly S. maltophilia were significantly associated with COVID-19 VAP. A high rate of bacterial resistance (25%), especially among Gram-negative bacteria, was found which may compromise patients' outcomes and has important implications in guiding therapeutic decisions in COVID-19 patients who acquire bacterial respiratory infections.
27 November 2023 in Open Forum Infectious Diseases
Mycobacterium simiae is a rare non-tuberculous mycobacterium (NTM) that is most identified in some Middle Eastern countries. It is unclear why this NTM is geographically restricted. The pathogen can either be a mere colonizer or cause significant morbidity. Patients with M. simiae infection require prolonged treatment with a combination of 3 antimicrobials. Drug resistance among M. simiae isolates can complicate the course of treatment. However, the correlation between in vitro resistance and clinical response is unknown. We aimed to report the susceptibility profile of M. simiae isolates from our institution and the prescribed treatments. We conducted a retrospective study of M. simiae isolates from the American University of Beirut Medical Center (AUBMC) over 19 years. All isolates were cultured at AUBMC using the Lowenstein-Jensen media and the BacT/ALERT system then referred for speciation and susceptibility testing at Mayo Clinic, MN, USA. We included 72 isolates that underwent susceptibility testing from 59 patients. Most isolates were obtained from sputum samples (61.1%) and the rest from bronchoalveolar lavages (BAL). The highest rates of susceptibility were to clarithromycin (84.7%) and amikacin (73.6%). All isolates were resistant to ciprofloxacin, streptomycin, doxycycline, and minocycline (Graph 1). Median minimal inhibitory concentrations (MIC) for clarithromycin and amikacin for susceptible isolates were 8 and 16 mcg/mL respectively. Clofazimine susceptibility was performed on only 16 isolates, 10 of which had an MIC ≤ 0.06 mcg/mL and the highest was 0.25 mcg/mL. Empiric antimicrobial therapy was given to 30% of patients but was inappropriate in 80% of cases. Targeted therapy was given to 40.9% of patients. Most received triple therapy with clarithromycin (95.8%) and clofazimine (41.7%) being the most common agents. The median duration of treatment was 12 months with the longest duration being 11 years. Microbiologic cure was achieved in 73.9% of the 23 patients who underwent repeated testing. TMP-SMX, trimethoprim-sulfamethoxazole. *Clofazimine was not included in this graph as there is no consensus on breakpoints for susceptibility for NTM. All our isolates had MICs ≤ 0.25 mcg/mL which is lower than breakpoints used in other studies. M. simiae exhibits resistance to most available antimycobacterial agents. Further research is needed to understand resistance mechanisms of this organism and correlate in vitro and in vivo findings. Souha S Kanj, MD, Gilead: Advisor/Consultant|Menarini: Advisor/Consultant|MSD: Advisor/Consultant|Pfizer: Advisor/Consultant